[CLSTR]
< Back to situation

[REVISION HISTORY]

Upadacitinib expanded approval for skin and arthritis

Updated 2 times since CLSTR started tracking revisions of this situation.

What changed

2026-09-22 15:14 UTC → 2026-10-06 12:59 UTC · added removed

Upadacitinib trials and expanded approval for skin disorders and arthritis

Clinical trials for the drug upadacitinib, a Janus kinase (JAK) inhibitor originally developed for rheumatoid arthritis, upadacitinib have demonstrated significant success in treating severe alopecia areata. Phase 3 clinical program results published in JAMA Dermatology indicate that the medication helps prevent the immune system from attacking hair follicles areata by blocking inflammatory signals via the JAK/STAT signaling pathway. In studies involving nearly 1,400 participants across North America, Europe, and China, Research indicates that up to 23 percent of patients with severe hair loss achieved complete scalp hair regrowth within six months. Further research led by Harvard University noted that months, while approximately half of the patients receiving the treatment achieved at least 80 percent hair regrowth within six months. Specifically, within regrowth. Following these developments, the 30 mg dosage group, 46 percent of patients experienced hair regrowth exceeding 90 percent. Expanding its clinical utility, upadacitinib European Commission has now received approval approved new indications for the treatment of both vitiligo and upadacitinib to treat three immune-mediated diseases. This authorization includes severe alopecia areata. In areata and non-segmental vitiligo patients, for adults and adolescents aged 12 and older. Additionally, the drug aims approval extends to prevent attacks active polyarticular juvenile idiopathic arthritis for patients from two years of age who have shown inadequate response or intolerance to disease-modifying antirheumatic drugs. The approval for non-segmental vitiligo is based on melanocytes Phase III Viti-Up clinical trials, which showed that a 15 mg daily dose achieved significant skin repigmentation compared to allow a placebo after 48 weeks. This makes upadacitinib the first authorized systemic treatment for non-segmental vitiligo within the repopulation of pigmented skin cells. European Union. While these expansions address what Antonio Costanzo, Vice President of Sidemast and Director of the Dermatology Specialization School at Humanitas University, stated during a press meeting in Milan that these new uses address Sidemast, described as a “high patient demand.” In Italy, the demand,” specific availability of the treatment is pending in Italy remains subject to approval from the Italian Medicines Agency (AIFA), a process that typically takes just under a year. (AIFA).

Versions

  1. 2026-10-06 12:59 UTC Upadacitinib expanded approval for skin and arthritis
  2. 2026-09-22 15:14 UTC Upadacitinib trials and expanded approval for skin disorders
  3. 2026-09-05 03:12 UTC Upadacitinib clinical trials for alopecia areata

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.